-0.000725747923554579 0.000483831949036386 0.000725747923554579 0.00395129425046363 -0.00266107571970001 0.00330618498508182 0.00395129425046363 -0.00249979840335459
Sign Up Today X
Thanks for submitting the form.
Stockreport

Biotech Bombshell: BioMarin's $4.8B Bet Ignites Amicus Shares in Rare-Disease Power Play [Yahoo! Finance]

BioMarin Pharmaceutical Inc. (BMRN)  More Company Research Source: Yahoo! Finance
Last biomarin pharmaceutical inc. earnings: 4/29 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.biomarin.com
Inc. ( NASDAQ:FOLD ) in a transaction valued at about $4.8 billion, a move that could strengthen BioMarin's position in rare-disease treatments. Under the terms, Amicus shareholders are set to receive $14.50 per share in cash, representing a 33% premium to the prior closing price, with the deal expected to close in the second quarter of 2026 subject to shareholder and regulatory approvals. The market response was swift, with Amicus shares jumping 31% in early New York trading and BioMarin rising 15%, marking their strongest single-day gains in years. Warning! GuruFocus has detected 8 Warning Signs with ARES. Is BMRN fairly valued? Test your thesis with our free DCF calculator. BioMarin Chief Executive Officer Alexander Hardy said the transaction makes strategic sense given BioMarin's commercial footprint and manufacturing capabilities, particularly as both companies focus on lysosomal storage disorders. The acquisition would give BioMarin access to approved treatments for Fabry [Read more]
IMPACT SNAPSHOT EVENT TIME: BMRN
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
BMRN alerts
from News Quantified
BMRN
NEWS
BMRN
Earnings
BMRN
Analyst Actions
BMRN
SEC Filings
Stockreport

Biotech Bombshell: BioMarin's $4.8B Bet Ignites Amicus Shares in Rare-Disease Power Play [Yahoo! Finance]

BioMarin Pharmaceutical Inc.  (BMRN) 
More Company Research Source: Yahoo! Finance
Last biomarin pharmaceutical inc. earnings: 4/29 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.biomarin.com
Inc. ( NASDAQ:FOLD ) in a transaction valued at about $4.8 billion, a move that could strengthen BioMarin's position in rare-disease treatments. Under the terms, Amicus shareholders are set to receive $14.50 per share in cash, representing a 33% premium to the prior closing price, with the deal expected to close in the second quarter of 2026 subject to shareholder and regulatory approvals. The market response was swift, with Amicus shares jumping 31% in early New York trading and BioMarin rising 15%, marking their strongest single-day gains in years. Warning! GuruFocus has detected 8 Warning Signs with ARES. Is BMRN fairly valued? Test your thesis with our free DCF calculator. BioMarin Chief Executive Officer Alexander Hardy said the transaction makes strategic sense given BioMarin's commercial footprint and manufacturing capabilities, particularly as both companies focus on lysosomal storage disorders. The acquisition would give BioMarin access to approved treatments for Fabry [Read more]
IMPACT SNAPSHOT
EVENT TIME:
BMRN
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Don't Miss Out On The Next BIG Stock Move
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS